Academic Health Center
Stay Connected
research-and-clinical-trials

New anti-HIV drug target identified by University of Minnesota researchers

University of Minnesota researchers have discovered a first-of-its-kind series of compounds possessing anti-human immunodeficiency virus (HIV) activity. The compounds present a new target for potential HIV drug development and future treatment options.

Complete findings are printed in today’s issue of The Journal of Virology.

The compounds, known as ribonucleoside analogs 8-azaadenosine, formycin A, 3-deazauridine, 5-fluorocytidine and 2’-C-methylcytidine, were found to stop the replication and spread of HIV by blocking HIV DNA synthesis or by inducing lethal mutagenesis.

Read more
research-and-clinical-trials

First pre-surgical breast cancer drug gets FDA approval

The FDA has just given approval to a biotech drug from Roche to be used as a pre-surgical treatment for one of the deadliest forms of breast cancer.

The drug, known as Perjeta, has doctors hoping they can shrink tumors earlier, making them easier to remove. This would allow more women to keep their breasts instead of pursuing a full mastectomy, as well as increase positive outcomes for patients…

Read more
research-and-clinical-trials

Drug design success propels efforts to fight HIV with a combination of two FDA-approved drugs

A University of Minnesota research team featuring researchers from the Institute for Molecular VirologySchool of Dentistry and Center for Drug Design has developed a new delivery system for a combination of two FDA approved drugs that may serve as an effective treatment for the human immunodeficiency virus (HIV).

The discovery, which allows for a combination of decitabine and gemcitabine to be delivered in pill form, marks a major step forward in patient feasibility for the drugs, which previously had been available solely via injection or intravenous therapy (IV).

The study, coauthored by Christine Clouser, Ph.D., Laurent Bonnac, Ph.D., Louis Mansky, Ph.D., and Steven Patterson, Ph.D., can be found “online first” in the journal Antiviral Chemistry & Chemotherapy.

Read more
news-and-notes

AHC game changer: Gunda Georg

Gunda Georg, Ph.D., is an esteemed researcher and professor in the College of Pharmacy at the University of Minnesota. As head of the Department of Medical Chemistry, Georg has made a tremendous impact in the field of synthetic medicinal chemistry.

Georg is also the director of the Institute for Therapeutics Discovery and Development and holds both the Robert Vince Endowed Chair in Medicinal Chemistry and McKnight Presidential Chair. This July she will receive the prestigious Volwiler Research Achievement Award for her research accomplishments.

Read more
research-and-clinical-trials

Minnesota Partnership Researchers Uncover Cancer Drug Prospects

A team funded by the Minnesota Partnership for Biotechnology and Medical Genomics has uncovered clues to possible drugs for two rare cancers through research involving baker’s yeast and a library of chemical compounds.

Read more
research-and-clinical-trials

Providing hope for people with rare diseases

February 28 is observed internationally as Rare Disease Day. Nearly 30 million people in the United States suffer from conditions classified as “rare diseases”.

While some bear names you’ve likely never heard of, other examples may surprise you …

Read more